This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Califf, R. M Search for Related Content PubMed PubMed Citation Articles by Califf, R. M Social Bookmarking                         What's this?

Clinical trials bureaucracy: unintended consequences of well-intentioned policy

Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA, calif001{at}mc.duke.edu

Background As randomized controlled trials have become the ‘gold standard’ for medical research, a complex regulatory structure for the conduct of clinical trials has emerged. However, this structure has not been adequately assessed to ensure that regulations governing human subjects research actually produce the desired effects.

Purpose Our purpose is to identify some of the major shortcomings in the current regulatory system of human clinical trials oversight, and to propose some potential solutions to these problems.

Methods We discuss the evolution of the current US regulatory environment and its application in the context of several widely-used drug therapies.

Results Despite numerous randomized controlled trials, performed within a structure of extensive documentation and data collection, serious shortcomings in a number of pharmaceutical therapies were not detected until after the drugs were approved and widely adopted by clinicians.

Conclusion The current system of regulatory bureaucracy in clinical trials has led to an extremely expensive research paradigm that, in spite of complex systems of oversight and exhaustive data collection, cannot be shown to adequately ensure the integrity of the research process and the protection of human research subjects. Some parts of the system, including Research Ethics Review Boards, may not be well-suited to carrying out their core mission of overseeing research conduct, and other aspects of clinical trials regulatory structure, such as monitoring/auditing review and adverse event reporting, may constitute a waste of money and resources. Misdirected data collection and adverse events reporting divert valuable resources and hamper development of large, simple clinical trials powered to definitively answer important research questions. Careful scrutiny of the utility of current or proposed regulatory schemes is required to ensure the integrity of human subjects research and to enhance the effectiveness of research dollars.

Clinical Trials, Vol. 3, No. 6, 496-502 (2006)
DOI: 10.1177/1740774506073173


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. W London, K. J Smalley, K. Conner, and J B. Smith The automation of clinical trial serious adverse event reporting workflow Clinical Trials, October 1, 2009; 6(5): 446 - 454. [Abstract] [PDF]

				E. L Eisenstein, R. Collins, B. S Cracknell, O. Podesta, E. D Reid, P. Sandercock, Y. Shakhov, M. L Terrin, M. A. Sellers, R. M Califf, et al. Sensible approaches for reducing clinical trial costs Clinical Trials, February 1, 2008; 5(1): 75 - 84. [Abstract] [PDF]

				E. Atallah, J. Cortes, S. O'Brien, S. Pierce, M. B. Rios, E. Estey, M. Markman, M. Keating, E. J. Freireich, and H. Kantarjian Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia Blood, November 15, 2007; 110(10): 3547 - 3551. [Abstract] [Full Text] [PDF]